Urinary Trypsin Inhibitor (UTI)

Specification

• Cat#: THP-0218
• Product Name: Urinary Trypsin Inhibitor (UTI)
• Description: Recombinant Ulinastatin produced in Yeast is a single, glycosylated, polypeptide having 143 amino acids, molecular mass of 20 kDa and predicted pI of 4.5.
• Sequences: AVLPQEEEGS GGGQLVTEVT KKEDSCQLGY SAGPCMGMTS RYFYNGTSMACETFQYGGCM GNGNNFVTEK ECLQTCRTVA ACNLPIVRGP CRAFIQLWAFDAVKGKCVLF PYGGCQGNGNKFYSEKECRE YCGVPGDGDE ELL
• Species: Human
• Molecular Weight: 20 kDa
• Source: Yeast
• Introduction: Urinary-Trypsin Inhibitor is a glucoprotein proteinase inhibitor with a molecular weight of about 67,000 derived from human urine which inhibits the activity of trypsin, chymotrypsin, lactate, lipase, hyaluronidase and various pancreatic enzymes. UTI is effective for acute pancreatitis, chronic recurrent pancreatitis and hemorrhagic, traumatic and endotoxic shocks. UTI is has strong inhibition effect to various protease, sugar and fat hydrolase. UTI precursor is proteolytically processed into distinct functioning proteins. urinary trypsin inhibitor belongs to the superfamily of Kunitztype protease inhibitors and plays an important role in many physiological and pathological processes. UTI gene is located on chromosome 9 in a cluster of lipocalin genes. High levels of UTI secretion is an early marker of renal tubular involvement and has radical scavenging activity. Bikunin localizes cell membrane. Free uristatin and bikunin pass readily into urine and are primarily bound to heavy chains that constitute the proinhibitor form in plasma. UTI particularly interacts with ORF3 protein of hepatitis E virus and in charge for enhancing alpha microglobulin export from the hepatocyte.
• Purity: >98.0% as determined by:(a) Analysis by RP-HPLC.(b) Anion-exchange FPLC.
• Formulation: Sterile Filtered solution. Formulated in 1X PBS.
• Endotoxin Level: <1 EU per 1 μg of the peptide by the LAL method
• Biological Activity: Greater than 3000U/mg as measured by BAEE method.

Pharmaceutical Information

• Pharmaceutical Application: Ulinastatin
• Applications: UTI is effective for acute pancreatitis, chronic recurrent pancreatitis and hemorrhagic, traumatic and endotoxic shocks.
• Examples of Clinical Use: Acute pancreatitis, chronic recurrent pancreatitis and hemorrhagic, traumatic and endotoxic shocks.
• Affected organisms: Humans

Related Reading

1. Introduction to Urinary Trypsin Inhibitor (UTI)

Urinary trypsin inhibitor (UTI) is a naturally occurring protein found in the urine and other bodily fluids. It is an endogenous inhibitor of serine proteases, which are enzymes that break down proteins in the body. UTI is primarily synthesized and excreted by the liver, and its level in the urine is regulated by the kidney. UTI has several physiological roles, including anti-inflammatory and anti-microbial effects. UTI inhibits complement activation, leukocyte migration, and cytokine production, all of which contribute to inflammation. Additionally, UTI has been shown to have anti-bacterial properties, as it inhibits the growth of certain bacteria, including uropathogenic Escherichia coli (E. coli). Due to its anti-inflammatory and anti-bacterial properties, UTI has been studied as a therapeutic agent for several conditions. It has been shown to be beneficial in the treatment of inflammatory bowel disease, acute pancreatitis, and sepsis. UTI has also been investigated as a potential treatment for urogenital infections, including urinary tract infections (UTIs), where its anti-bacterial activity is thought to play a role in preventing or treating infection.

In summary, urinary trypsin inhibitor (UTI) is a naturally occurring protein with anti-inflammatory and anti-microbial properties. It has several physiological roles and has been investigated as a therapeutic agent for various conditions, including inflammatory bowel disease, acute pancreatitis, and urogenital infections. Further research is needed to fully understand the potential benefits of UTI as a therapeutic agent.

2. Function and approach of Urinary Trypsin Inhibitor (UTI)

The primary function of urinary trypsin inhibitor (UTI) is to inhibit serine proteases, which are enzymes that break down proteins in the body. This is important to prevent the excessive breakdown of proteins and maintain the normal function and structure of tissues. UTI also has anti-inflammatory properties that help to reduce inflammation in the body. It inhibits complement activation, leukocyte migration, and cytokine production, all of which contribute to inflammation. In addition, UTI has been shown to have anti-bacterial properties, as it inhibits the growth of certain bacteria, including uropathogenic Escherichia coli (E. coli). This suggests that UTI may be useful in the prevention and treatment of urinary tract infections (UTIs).

The approach of UTI as a therapeutic agent involves the administration of exogenous UTI to supplement the naturally occurring UTI in the body. This can be done by intravenous infusion, oral administration, or even as a topical treatment. Research has shown that UTI can be effective in treating several conditions, including inflammatory bowel disease, acute pancreatitis, sepsis, and urogenital infections such as UTIs.

However, further research is needed to fully understand the potential benefits of UTI and its mechanism of action in treating these conditions. It is also important to understand the side effects and potential risks associated with the use of UTI as a therapeutic agent.

3. Medical application of Urinary Trypsin Inhibitor (UTI)

Urinary Trypsin Inhibitor (UTI) has several medical applications due to its anti-inflammatory, anti-bacterial, and proteinase inhibitory properties. Some of the medical applications of UTI are:

1. Urinary tract infections (UTIs): UTI is effective in treating and preventing recurrent UTIs caused by E. coli. It helps to stop the growth and adherence of bacteria to the urinary tract mucosa and reduces the inflammation caused by the infection, thus speeding up recovery.
2. Acute pancreatitis: An intravenous UTI infusion is effective in reducing the severity and complications of acute pancreatitis by localizing pancreatic damage and decreasing systemic inflammation.
3. Inflammatory bowel disease (IBD): UTI has been shown to reduce inflammation in the intestine and prevent the development of colitis in animal models. Medical studies have suggested the potential role of UTI in the management of inflammatory bowel disease in humans.
4. Sepsis: UTI can control pulmonary inflammation in sepsis patients. It has been shown to be effective in reducing the mortality and morbidity of patients with sepsis.
5. ARDS (Acute Respiratory Distress Syndrome): Intravenous infusion of UTI has been shown promising results in animal studies in reducing lung damage and inflammation in ARDS.
6. Cardiovascular diseases: UTI has preventive effects on thrombosis and atherosclerosis and can protect from the increase in inflammatory markers associated with chronic heart failure.

Further, UTI might also have potential applications as a component of cosmetics and skin care products, oral care formulations, and food supplements. Nonetheless, further studies are ongoing to identify the full spectrum of medical application of UTI and its effective dosage.